Devalingam Mahalingam: Clinical Trials

3 trials sponsored by Devalingam Mahalingam, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 no longer available, 1 recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Recruiting 1, Withdrawn 1
Phase 22Recruiting 1, Withdrawn 1

Follow Devalingam Mahalingam: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Hepatocellular Carcinoma, Cirrhosis
Phase 1 / Phase 2RecruitingDevalingam Mahalingam592026-03-302026-10-23
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Sotorasib, Liposomal Irinotecan (nal-IRI), 5 Fluorouracil (5FU) - Pancreatic Cancer, Unresectable Pancreatic Cancer
Phase 1 / Phase 2WithdrawnDevalingam Mahalingam2022-09-132023-05-11
Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
G-202 - Hepatocellular Carcinoma
No longer availableDevalingam Mahalingam2014-03-10

Conditions studied

Carcinoma, Hepatocellular (2)  ·  Fibrosis (1)  ·  Pancreatic Neoplasms (1)

Interventions

Albumin-Bound Paclitaxel (1)  ·  Fluorouracil (1)  ·  Gemcitabine (1)  ·  Leucovorin (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Specimen Handling (1)  ·  Taxes (1)  ·  irinotecan sucrosofate (1)  ·  sotorasib (1)

Countries

United States (2)

NIH funding

P30CA060553 (1)